Cargando…
Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status?
OBJECTIVE: The aim of this study was to determine the role of contrast-enhanced computed tomography (CE-CT) parameters in predicting the expression status of HER2 in gastric adenocarcinoma (GAC) patients before radical gastrectomy. MATERIALS AND METHODS: A total of 460 GAC patients who underwent non...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035892/ https://www.ncbi.nlm.nih.gov/pubmed/32110095 http://dx.doi.org/10.2147/CMAR.S230138 |
_version_ | 1783500133441208320 |
---|---|
author | Wang, Na Wang, Xinxin Li, Wenya Ye, Huajun Bai, Hongzhao Wu, Jiansheng Chen, Mengjun |
author_facet | Wang, Na Wang, Xinxin Li, Wenya Ye, Huajun Bai, Hongzhao Wu, Jiansheng Chen, Mengjun |
author_sort | Wang, Na |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to determine the role of contrast-enhanced computed tomography (CE-CT) parameters in predicting the expression status of HER2 in gastric adenocarcinoma (GAC) patients before radical gastrectomy. MATERIALS AND METHODS: A total of 460 GAC patients who underwent non-contrast CT (NC-CT) and CE-CT examinations before radical resection were enrolled in this retrospective study. The radiologists reviewed their CT scans and recorded parameters, including CT attenuate value (CAV) and corrected CAV (cCAV). The pathologist identified the postoperative HER2 expression status, and HER2 expression status was evaluated by immunohistochemical staining (IHC). The association between CE-CT parameters and HER2 expression status was analyzed. RESULTS: Among the 460 patients, 84 patients had HER2 over-expression status, at a prevalence of 18.3%. The CAVs were significantly different between the 2 different HER2 expression groups in the non-contrast and arterial phases (non-contrast phase: p = 0.005; arterial phase: p < 0.001). Besides, there was a significant difference in the cCAVs between the 2 groups in the arterial phase (arterial phase: p = 0.003). Univariate and multivariate logistic regression analyses identified that the maximum diameter of tumor, differentiation degree, CAV in non-contrast, arterial, and portal phases, and cCAV in the arterial phase were predictive factors of HER2 expression status. CONCLUSION: Our analyses showed that the CE-CT parameters were significantly different between different HER2 expression groups. CE-CT parameters could serve as simple, objective predictive factors of HER2 expression status of GAC patients. |
format | Online Article Text |
id | pubmed-7035892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70358922020-02-27 Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? Wang, Na Wang, Xinxin Li, Wenya Ye, Huajun Bai, Hongzhao Wu, Jiansheng Chen, Mengjun Cancer Manag Res Original Research OBJECTIVE: The aim of this study was to determine the role of contrast-enhanced computed tomography (CE-CT) parameters in predicting the expression status of HER2 in gastric adenocarcinoma (GAC) patients before radical gastrectomy. MATERIALS AND METHODS: A total of 460 GAC patients who underwent non-contrast CT (NC-CT) and CE-CT examinations before radical resection were enrolled in this retrospective study. The radiologists reviewed their CT scans and recorded parameters, including CT attenuate value (CAV) and corrected CAV (cCAV). The pathologist identified the postoperative HER2 expression status, and HER2 expression status was evaluated by immunohistochemical staining (IHC). The association between CE-CT parameters and HER2 expression status was analyzed. RESULTS: Among the 460 patients, 84 patients had HER2 over-expression status, at a prevalence of 18.3%. The CAVs were significantly different between the 2 different HER2 expression groups in the non-contrast and arterial phases (non-contrast phase: p = 0.005; arterial phase: p < 0.001). Besides, there was a significant difference in the cCAVs between the 2 groups in the arterial phase (arterial phase: p = 0.003). Univariate and multivariate logistic regression analyses identified that the maximum diameter of tumor, differentiation degree, CAV in non-contrast, arterial, and portal phases, and cCAV in the arterial phase were predictive factors of HER2 expression status. CONCLUSION: Our analyses showed that the CE-CT parameters were significantly different between different HER2 expression groups. CE-CT parameters could serve as simple, objective predictive factors of HER2 expression status of GAC patients. Dove 2020-02-18 /pmc/articles/PMC7035892/ /pubmed/32110095 http://dx.doi.org/10.2147/CMAR.S230138 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Na Wang, Xinxin Li, Wenya Ye, Huajun Bai, Hongzhao Wu, Jiansheng Chen, Mengjun Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title_full | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title_fullStr | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title_full_unstemmed | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title_short | Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? |
title_sort | contrast-enhanced ct parameters of gastric adenocarcinoma: can radiomic features be surrogate biomarkers for her2 over-expression status? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035892/ https://www.ncbi.nlm.nih.gov/pubmed/32110095 http://dx.doi.org/10.2147/CMAR.S230138 |
work_keys_str_mv | AT wangna contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT wangxinxin contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT liwenya contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT yehuajun contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT baihongzhao contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT wujiansheng contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus AT chenmengjun contrastenhancedctparametersofgastricadenocarcinomacanradiomicfeaturesbesurrogatebiomarkersforher2overexpressionstatus |